Jessica Nye

1 week ago | endocrinologyadvisor.com | Jessica Nye

Live births with in vitro fertilization (IVF) are more likely among women with thicker endometrial thickness (EMT) up to 15 mm. These findings were published in Fertility and Sterility. A large body of literature has focused on the association between EMT and pregnancy rates. However, no studies have evaluated the effect of EMT on IVF outcomes.

1 week ago | rheumatologyadvisor.com | Jessica Nye

Additional relevant safety signals associated with apremilast use have been identified, according to the results of a study published in Archives of Dermatological Research. Apremilast is a small molecule phosphodiesterase-4 inhibitor that is approved by the United States (US) Food and Drug Administration (FDA) for the management of psoriatic arthritis and plaque psoriasis.

1 week ago | endocrinologyadvisor.com | Jessica Nye

Use of growth hormone (GH) for the treatment of adult-onset craniopharyngioma does not lower risk for liver disease, according to results of a study published in the Journal of the Endocrine Society. Craniopharyngioma has a bimodal incidence rate, occurring primarily at 0 to 19 years of age or 40 to 79 years of age. After surgical intervention for adult-onset craniopharyngioma, patients often experience rapid weight gain, and half develop metabolic syndrome.

1 week ago | thecardiologyadvisor.com | Jessica Nye

Sleep duration may mediate the relationship between diet and insulin resistance (IR), according to results of a study published in Lipids in Health and Disease. Prior study findings suggest an association of both sleep and diet with IR risk. Investigators from Guangzhou Medical University in China hypothesized that sleep duration mediated the relationship between diets with high viable microbes and both lower risk for IR and lower triglyceride-glucose (TyG) index.

1 week ago | dermatologyadvisor.com | Jessica Nye

A systematic review and meta-analysis published in Dermatitis found that anti-OX40 therapies are effective at treating moderate to severe atopic dermatitis (AD) and have an acceptable safety profile. Anti-OX40 therapies are a group of novel therapeutics that target the OX40 pathway, which is a costimulatory receptor on activated T cells that are involved in inflammatory responses and the maintenance of immune memory.